| Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, ... The lancet oncology 22 (7), 946-958, 2021 | 158 | 2021 |
| NK-cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo DA Vallera, S Ferrone, B Kodal, P Hinderlie, L Bendzick, B Ettestad, ... Cancers 12 (9), 2659, 2020 | 90 | 2020 |
| Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure? A Rao, N Vapiwala, EM Schaeffer, CJ Ryan American Society of Clinical Oncology Educational Book 39, 309-320, 2019 | 64 | 2019 |
| Survival outcomes for advanced kidney cancer patients in the era of targeted therapies A Rao, C Wiggins, RC Lauer Annals of Translational Medicine 6 (9), 2018 | 53 | 2018 |
| Telehealth in cancer care during COVID-19: disparities by age, race/ethnicity, and residential status PI Jewett, RI Vogel, R Ghebre, JYC Hui, HM Parsons, A Rao, S Sagaram, ... Journal of Cancer Survivorship 16 (1), 44-51, 2022 | 52 | 2022 |
| Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell … CH Lee, AY Shah, JJ Hsieh, A Rao, A Pinto, MA Bilen, AL Cohn, ... Journal of Clinical Oncology 38 (15_suppl), 5008-5008, 2020 | 49 | 2020 |
| Interrupted abdominal closure prevents burst: randomized controlled trial comparing interrupted-x and conventional continuous closures in surgical and gynecological patients CS Agrawal, P Tiwari, S Mishra, A Rao, NS Hadke, S Adhikari, ... Indian Journal of Surgery 76, 270-276, 2014 | 39 | 2014 |
| Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer—where are we now? A Rao, N Moka, DA Hamstra, CJ Ryan Cancers 14 (3), 801, 2022 | 35 | 2022 |
| Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients AA Kulkarni, N Rubin, A Tholkes, S Shah, CJ Ryan, PL Lutsey, A Prizment, ... Esmo Open 6 (5), 100261, 2021 | 31 | 2021 |
| A review of avelumab in locally advanced and metastatic bladder cancer A Rao, MR Patel Therapeutic advances in urology 11, 1756287218823485, 2019 | 27 | 2019 |
| A phase Ib/II study of the CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer I De Kouchkovsky, A Rao, BA Carneiro, L Zhang, C Lewis, A Phone, ... Clinical Cancer Research 28 (8), 1531-1539, 2022 | 19 | 2022 |
| CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration … A Rao, CJ Ryan, DJ VanderWeele, G Heller, LD Lewis, C Watt, RC Chen, ... Journal of Clinical Oncology 39 (6_suppl), TPS181-TPS181, 2021 | 17 | 2021 |
| A phase Ib trial of neoadjuvant/adjuvant durvalumab+/-tremelimumab in locally advanced renal cell carcinoma (RCC). MC Ornstein, J Zabell, LS Wood, B Hobbs, S Devonshire, A Martin, ... Journal of Clinical Oncology 38 (15_suppl), 5021-5021, 2020 | 16 | 2020 |
| PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19) R Aggarwal, G Heller, DW Hillman, H Xiao, J Picus, ME Taplin, T Dorff, ... Journal of Clinical Oncology 42 (10), 1114-1123, 2024 | 14 | 2024 |
| Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical … AA Ganaie, AP Mansini, T Hussain, A Rao, HR Siddique, A Shabaneh, ... Molecular cancer therapeutics 19 (12), 2598-2611, 2020 | 14 | 2020 |
| Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma A Rao, R Lauer The oncologist 20 (4), 370-371, 2015 | 13 | 2015 |
| Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study. A Rao, D Morris, VJ Assikis, GG Jha, CJ Ryan, AJ Ablaza, J Habeck, ... Journal of Clinical Oncology 39 (6_suppl), 79-79, 2021 | 9 | 2021 |
| Paralyzed by a rare cause: an unusual case of metastatic diffuse large B cell lymphoma of the intramedullary spinal cord A Rao, R Griffiths, K Arnaoutakis Annals of hematology 93, 337-338, 2014 | 9 | 2014 |
| LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19) R Aggarwal, G Heller, D Hillman, H Xiao, J Picus, J Wang, ME Taplin, ... Annals of Oncology 33, S1428, 2022 | 7 | 2022 |
| Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC). RR McKay, PC Barata, A Elliott, MA Bilen, EF Burgess, S Darabi, ... Journal of Clinical Oncology 40 (6_suppl), 287-287, 2022 | 7 | 2022 |
Mehmet Asim BilenWinship Cancer Institute of Emory University確認したメール アドレス: emory.edu
